Jason Fangusaro

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8664773/publications.pdf

Version: 2024-02-01

66 papers	3,863 citations	147801 31 h-index	128289 60 g-index
66 all docs	66 docs citations	66 times ranked	4524 citing authors

#	Article	IF	Citations
1	Pediatric Central Nervous System Germ Cell Tumors: A Review. Oncologist, 2008, 13, 690-699.	3.7	370
2	Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncology, The, 2019, 20, 1011-1022.	10.7	315
3	A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study. Neuro-Oncology, 2017, 19, 1135-1144.	1.2	236
4	Survivin splice variants regulate the balance between proliferation and cell death. Oncogene, 2005, 24, 1994-2007.	5.9	176
5	Consensus on the management of intracranial germ-cell tumours. Lancet Oncology, The, 2015, 16, e470-e477.	10.7	173
6	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. Lancet Oncology, The, 2012, 13, 838-848.	10.7	148
7	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. Acta Neuropathologica, 2014, 128, 291-303.	7.7	141
8	Pediatric High Grade Glioma: a Review and Update on Tumor Clinical Characteristics and Biology. Frontiers in Oncology, 2012, 2, 105.	2.8	137
9	Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomasâ€”a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2014, 16, 310-317.	1.2	132
10	Intensive chemotherapy followed by consolidative myeloablative chemotherapy with autologous hematopoietic cell rescue (AuHCR) in young children with newly diagnosed supratentorial primitive neuroectodermal tumors (sPNETs): Report of the Head Start I and II experience. Pediatric Blood and Cancer, 2008, 50, 312-318.	1.5	125
11	Essential Role for Survivin in Early Brain Development. Journal of Neuroscience, 2005, 25, 6962-6970.	3.6	116
12	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	1.2	116
13	Response assessment in paediatric low-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e305-e316.	10.7	115
14	Variable response to propranolol treatment of kaposiform hemangioendothelioma, tufted angioma, and Kasabachâ€“Merritt phenomenon. Pediatric Blood and Cancer, 2012, 59, 934-938.	1.5	107
15	Management of pediatric low-grade glioma. Current Opinion in Pediatrics, 2019, 31, 21-27.	2.0	87
16	Pediatric High-Grade Gliomas and Diffuse Intrinsic Pontine Gliomas. Journal of Child Neurology, 2009, 24, 1409-1417.	1.4	84
17	Phase I Trial of Lenalidomide in Pediatric Patients With Recurrent, Refractory, or Progressive Primary CNS Tumors: Pediatric Brain Tumor Consortium Study PBTC-018. Journal of Clinical Oncology, 2011, 29, 324-329.	1.6	83
18	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82

#	Article	IF	Citations
19	Phase II Trial of Response-Based Radiation Therapy for Patients With Localized CNS Nongerminomatous Germ Cell Tumors: A Children's Oncology Group Study. Journal of Clinical Oncology, 2019, 37, 3283-3290.	1.6	78
20	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
21	Rethinking childhood ependymoma: a retrospective, multi-center analysis reveals poor long-term overall survival. Journal of Neuro-Oncology, 2017, 135, 201-211.	2.9	72
22	A phase II trial of selumetinib in children with recurrent optic pathway and hypothalamic low-grade glioma without NF1: a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2021, 23, 1777-1788.	1.2	68
23	Response to bevacizumab, irinotecan, and temozolomide in children with relapsed medulloblastoma: a multi-institutional experience. Child's Nervous System, 2013, 29, 589-596.	1.1	66
24	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. Acta Neuropathologica, 2020, 139, 223-241.	7.7	65
25	Improved neuropsychological outcomes following proton therapy relative to X-ray therapy for pediatric brain tumor patients. Neuro-Oncology, 2019, 21, 934-943.	1.2	51
26	Lack of efficacy of bevacizumab + irinotecan in cases of pediatric recurrent ependymoma--a Pediatric Brain Tumor Consortium study. Neuro-Oncology, 2012, 14, 1404-1412.	1.2	50
27	REST Is a Novel Prognostic Factor and Therapeutic Target for Medulloblastoma. Molecular Cancer Therapeutics, 2012, 11, 1713-1723.	4.1	47
28	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. Neuro-Oncology, 2020, 22, 773-784.	1.2	44
29	Aggressive variant of a papillary glioneuronal tumor. Journal of Neurosurgery: Pediatrics, 2009, 3, 46-52.	1.3	43
30	Phase II trial of pegylated interferon alfa-2b in young patients with neurofibromatosis type 1 and unresectable plexiform neurofibromas. Neuro-Oncology, 2017, 19, now158.	1.2	41
31	Bevacizumab (BVZ)â€associated toxicities in children with recurrent central nervous system tumors treated with BVZ and irinotecan (CPTâ€11). Cancer, 2013, 119, 4180-4187.	4.1	33
32	Evaluation of age-dependent treatment strategies for children and young adults with pineoblastoma: analysis of pooled European Society for Paediatric Oncology (SIOP-E) and US Head Start data. Neuro-Oncology, 2017, 19, now234.	1.2	33
33	MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus. Neuro-Oncology, 2022, 24, 1845-1856.	1.2	30
34	Bevacizumab and irinotecan in the treatment of children with recurrent/refractory medulloblastoma. Pediatric Blood and Cancer, 2011, 56, 491-494.	1.5	27
35	Evaluating the incidence and utility of microscopic metastatic dissemination as diagnosed by lumbar cerebro-spinal fluid (CSF) samples in children with newly diagnosed intracranial ependymoma. Journal of Neuro-Oncology, 2011, 103, 693-698.	2.9	24
36	Unclear standard of care for pediatric high grade glioma patients. Journal of Neuro-Oncology, 2013, 113, 341-342.	2.9	22

#	Article	IF	Citations
37	Incidental Resolution of a Radiation-Induced Cavernous Hemangioma of the Brain following the Use of Bevacizumab in a Child with Recurrent Medulloblastoma. Pediatric Neurosurgery, 2010, 46, 303-307.	0.7	19
38	Transcriptional repressor REST drives lineage stageâ€“specific chromatin compaction at Ptch1 and increases AKT activation in a mouse model of medulloblastoma. Science Signaling, 2019, 12, .	3.6	19
39	Bevacizumab-Associated Osteonecrosis of the Wrist and Knee in Three Pediatric Patients With Recurrent CNS Tumors. Journal of Clinical Oncology, 2013, 31, e24-e27.	1.6	18
40	Improving vaccine efficacy against malignant glioma. OncoImmunology, 2016, 5, e1196311.	4.6	16
41	Clinical Pharmacokinetics and Pharmacodynamics of Selumetinib. Clinical Pharmacokinetics, 2021, 60, 283-303.	3.5	16
42	Nonâ€cerebellar primitive neuroectodermal tumors (PNET): Summary of the Milan consensus and state of the art workshop on marrow ablative chemotherapy with hematopoietic cell rescue for malignant brain tumors of childhood and adolescents. Pediatric Blood and Cancer, 2010, 54, 638-640.	1.5	14
43	Advanced ADC Histogram, Perfusion, and Permeability Metrics Show an Association with Survival and Pseudoprogression in Newly Diagnosed Diffuse Intrinsic Pontine Glioma: A Report from the Pediatric Brain Tumor Consortium. American Journal of Neuroradiology, 2020, 41, 718-724.	2.4	14
44	Severe Radiation Necrosis Successfully Treated With Bevacizumab in an Infant with Lowâ€Grade Glioma and Tumorâ€Associated Intractable Trigeminal Neuralgia. Pediatric Blood and Cancer, 2016, 63, 1671-1673.	1.5	13
45	Clinical phenotypes and prognostic features of embryonal tumours with multi-layered rosettes: a Rare Brain Tumor Registry study. The Lancet Child and Adolescent Health, 2021, 5, 800-813.	5.6	12
46	REST upregulates gremlin to modulate diffuse intrinsic pontine glioma vasculature. Oncotarget, 2018, 9, 5233-5250.	1.8	12
47	Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials. Neuro-Oncology, 2022, 24, 1950-1961.	1.2	12
48	Advances in the classification and treatment of pediatric brain tumors. Current Opinion in Pediatrics, 2021, 33, 26-32.	2.0	11
49	Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma. Pediatric Blood and Cancer, 2008, 50, 699-700.	1.5	9
50	Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: A Pediatric Brain Tumor Consortium trial. Pediatric Blood and Cancer, 2021, 68, e28756.	1.5	9
51	Phase 2 Study of Pomalidomide (CC-4047) Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors. Frontiers in Oncology, 2021, 11, 660892.	2.8	7
52	A Phase 2 Trial of Response-Based Radiation Therapy for Localized Central Nervous System Germ Cell Tumors: Patterns of Failure and Radiation Dosimetry for Nongerminomatous Germ Cell Tumors. International Journal of Radiation Oncology Biology Physics, 2022, 113, 143-151.	0.8	7
53	Introduction to a Special Issue on Pediatric Neuro-Oncology. Journal of Child Neurology, 2009, 24, 1341-1342.	1.4	5
54	Glioblastoma Multiforme in a Patient With Chronic Granulomatous Disease Treated With Subtotal Resection, Radiation, and Thalidomide. Journal of Pediatric Hematology/Oncology, 2009, 31, 965-969.	0.6	5

#	Article	IF	Citations
55	Successful treatment of metastatic Î²HCG-secreting germ cell tumor occurring 3Âyears after total resection of a pineal mature teratoma. European Journal of Pediatrics, 2014, 173, 1011-5.	2.7	5
56	The â€œRiskâ€•in Pediatric Low-Grade Glioma. Cancer Cell, 2020, 37, 424-425.	16.8	5
57	Multicenter Analysis of Genomically Targeted Single Patient Use Requests for Pediatric Neoplasms. Journal of Clinical Oncology, 2021, 39, 3822-3828.	1.6	4
58	Imaging response assessment for CNS germ cell tumours: consensus recommendations from the European Society for Paediatric Oncology Brain Tumour Group and North American Children's Oncology Group. Lancet Oncology, The, 2022, 23, e218-e228.	10.7	4
59	Recurrent pure CNS germinoma with markedly elevated serum and cerebrospinal fluid human chorionic gonadotropinâ€beta (HCGÎ²). Pediatric Blood and Cancer, 2011, 56, 863-864.	1.5	3
60	Neonatal Central Nervous System Tumors. Clinics in Perinatology, 2021, 48, 35-51.	2.1	3
61	ADC Histogram Analysis of Pediatric Low-Grade Glioma Treated with Selumetinib: A Report from the Pediatric Brain Tumor Consortium. American Journal of Neuroradiology, 2022, 43, 455-461.	2.4	3
62	Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact on Clinical Care. JCO Precision Oncology, 2022, 6, e2100451.	3.0	3
63	Longâ€term survival in a pediatric patient with supratentorial primitive neuroâ€ectodermal tumor and extraneural metastasis at diagnosis. Pediatric Blood and Cancer, 2011, 57, 341-344.	1.5	2
64	Involvement of the neural stem cell compartment by pediatric and adult gliomas: a retrospective review of 377 cases. Journal of Neuro-Oncology, 2015, 122, 105-110.	2.9	2
65	Radiation therapy approaches do not currently improve overall survival in young children with sPNET as compared to the Head Start I and II experience. Pediatric Blood and Cancer, 2008, 51, 149-150.	1.5	1
66	NFB-04. Evaluating focal areas of signal intensity (FASI) in children with neurofibromatosis type-1 (NF1) treated with selumetinib on PBTC-029B. Neuro-Oncology, 2022, 24, i128-i129.	1.2	0